MedTrace Logo

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

NCT01010945 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2024-11-21

No results posted yet for this study

Summary

This is a phase 1b study to evaluate the combination of gemcitabine and Tarceva (erlotinib) and nab-paclitaxel in patients with advanced pancreatic cancer.

Conditions

  • Advanced Pancreatic Cancer

Interventions

DRUG

erlotinib

administered orally

DRUG

gemcitabine

administered intravenously

DRUG

nab-paclitaxel

administered intravenously

Sponsors & Collaborators

  • OSI Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Astellas Pharma Global Development

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-03
Primary Completion
2012-01-25
Completion
2012-01-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01010945 on ClinicalTrials.gov